Intensity Therapeutics is pioneering a novel approach to cancer treatment through its proprietary drug product, INT230-6. This formulation combines a unique cell penetration enhancer, SHAO, with established chemotherapeutic agents cisplatin and vinblastine. The innovative delivery method allows for direct intratumoral administration, which enhances the dispersion of the drugs throughout the tumor and facilitates their absorption into cancer cells. This localized treatment not only induces significant tumor necrosis but also activates a systemic immune response, enabling the immune system to target both the injected tumor and distant metastatic sites. Clinical studies have shown promising results, indicating that INT230-6 can improve overall survival rates in patients with various metastatic cancers.

The technology behind INT230-6 addresses the limitations of traditional intravenous chemotherapy, which often results in suboptimal drug concentrations at tumor sites and significant toxicity. By utilizing a targeted intratumoral approach, INT230-6 aims to maximize therapeutic efficacy while minimizing adverse effects. Ongoing clinical trials, including the Phase 3 INVINCIBLE-3 study, are evaluating the safety and effectiveness of INT230-6 compared to standard-of-care treatments for patients with locally recurrent or metastatic soft tissue sarcomas. The results from these studies are expected to further validate the potential of INT230-6 as a transformative treatment option in oncology, particularly for patients with advanced and refractory cancers.

United States

Intensity Therapeutics is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. We leverage our DfuseRxSM technology platform to create new drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Our lead product candidate, INT230-6, is currently being evaluated in a Phase 1/2 clinical study in patients with various types of advanced solid tumors. INT230-6 has the potential to induce an adaptive immune response that not only attacks the injected tumor, but also non-injected tumors and unseen micro-metastases.

Cancer

Digestive System Diseases

Endocrine System Diseases

Intensity Therapeutics

Sarcoma

INT230-6

Biologics

Soft tissue sarcoma

<p class="font_7">INT230-6, Intensity's lead proprietary investigational product candidate, is designed for direct intratumoral injection. INT230-6 was discovered using Intensity's proprietary DfuseRx℠ technology platform. The drug is composed of two proven, potent anti-cancer agents, cisplatin and vinblastine, and a penetration enhancer molecule (SHAO) that helps disperse potent cytotoxic drugs throughout tumors for diffusion into cancer cells. These agents remain in the tumor resulting in a favorable safety profile. In addition to local disease control, direct killing of the tumor by INT230-6 releases a bolus of neoantigens specific to the patient's malignancy, leading to engagement of the immune system and systemic anti-tumor effects. Importantly, these effects are mediated without immunosuppression that so often occurs with systemic chemotherapy.</p>

Intensity Therapeutics

Company Details